HomeCategoryOcular Surface Diseases - Verséa

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/11/thumb.jpg?resize=1280%2C640&ssl=1

As part of the corporate exhibit hall interview series at the Eyes On 2023, Verséa Ophthalmics President, Rob Sambursky, MD, was interviewed by Brittany J. McMurren, OD. During the interview, titled “A Deep Dive into New Testing & Therapeutic Innovations”  Rob Sambursky, MD presented new testing and therapeutic innovations that Verséa Ophthalmics is bringing to...

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/10/rob-sambursky-zoom-interview.jpg?resize=600%2C400&ssl=1

Following the American Academy of Ophthalmology (AAO) 2022 Annual Meeting held in Chicago, Verséa Ophthalmics President, Rob Sambursky, MD, was interviewed by Ophthalmology Times to provide an overview of the company and its products. Dr. Sambursky spoke about BIOVANCE 3L Ocular, a 3-layered decellularized, dehydrated human amniotic membrane (DDhAM) designed for comfort and improved handleability,...

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/10/sandiego-scaled.jpg?resize=1280%2C640&ssl=1

This week Verséa Ophthalmics team is presenting at the American Academy of Optometry AAOpt 2022 Meeting in San Diego (CA). Visit our booth # 405, where we will be demonstrating our new Tear-Based Point of Care (T-POC) Quantitative Testing Platform that consists of a portable, multifunctional reader and two tear-based quantitative biomarker test kits: –...

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/09/Verséa-Ophthalmics-Diagnostic-Platform_Page_1.jpg?resize=1190%2C640&ssl=1

New innovative, rapid, tear-based, POC diagnostic test platform is designed specifically to assist eye-care clinicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders   At this year’s Expo of the American Academy of Ophthalmology AAO 2022 – booth # 1251, Verséa Ophthalmics is launching their comprehensive Product Portfolio and demonstrating...